Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.

MLA

Kaito, Yuta, et al. “Immune Checkpoint Molecule DNAM-1/CD112 Axis Is a Novel Target for Natural Killer-Cell Therapy in Acute Myeloid Leukemia.” Haematologica, vol. 109, no. 4, Apr. 2024, pp. 1107–20. EBSCOhost, https://doi.org/10.3324/haematol.2023.282915.

APA

Kaito, Y., Sugimoto, E., Nakamura, F., Tsukune, Y., Sasaki, M., Yui, S., Yamaguchi, H., Goyama, S., Nannya, Y., Mitani, K., Tamura, H., & Imai, Y. (2024). Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia. Haematologica, 109(4), 1107–1120. https://doi.org/10.3324/haematol.2023.282915

Chicago

Kaito, Yuta, Emi Sugimoto, Fumi Nakamura, Yutaka Tsukune, Makoto Sasaki, Shunsuke Yui, Hiroki Yamaguchi, et al. 2024. “Immune Checkpoint Molecule DNAM-1/CD112 Axis Is a Novel Target for Natural Killer-Cell Therapy in Acute Myeloid Leukemia.” Haematologica 109 (4): 1107–20. doi:10.3324/haematol.2023.282915.